Throughout the last three months, 8 analysts have evaluated Accolade ACCD, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 4 | 1 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.81, along with a high estimate of $8.00 and a low estimate of $5.00. Experiencing a 18.05% decline, the current average is now lower than the previous average price target of $8.31.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Accolade is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ricky Goldwasser | Morgan Stanley | Lowers | Equal-Weight | $5.00 | $6.00 |
| Stan Berenshteyn | Wells Fargo | Lowers | Equal-Weight | $6.00 | $7.00 |
| Jailendra Singh | Truist Securities | Lowers | Buy | $7.50 | $9.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $7.00 | $13.00 |
| Stephanie Davis | Barclays | Lowers | Equal-Weight | $5.00 | $5.50 |
| Jeff Garro | Stephens & Co. | Lowers | Overweight | $8.00 | $10.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $8.00 | $8.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $8.00 | $8.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Accolade. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Accolade compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Accolade's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Accolade's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Accolade analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Accolade
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Accolade: Financial Performance Dissected
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Accolade showcased positive performance, achieving a revenue growth rate of 9.8% as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Accolade's net margin excels beyond industry benchmarks, reaching -22.5%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Accolade's ROE excels beyond industry benchmarks, reaching -5.58%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Accolade's ROA excels beyond industry benchmarks, reaching -3.14%. This signifies efficient management of assets and strong financial health.
Debt Management: Accolade's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.56.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
